MX2020010879A - Carboxamidas biciclicas y metodos de uso de las mismas. - Google Patents
Carboxamidas biciclicas y metodos de uso de las mismas.Info
- Publication number
- MX2020010879A MX2020010879A MX2020010879A MX2020010879A MX2020010879A MX 2020010879 A MX2020010879 A MX 2020010879A MX 2020010879 A MX2020010879 A MX 2020010879A MX 2020010879 A MX2020010879 A MX 2020010879A MX 2020010879 A MX2020010879 A MX 2020010879A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- methods
- receptors
- carboxamides
- bicyclic
- Prior art date
Links
- -1 Bicyclic carboxamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659068P | 2018-04-17 | 2018-04-17 | |
| US201862746843P | 2018-10-17 | 2018-10-17 | |
| PCT/US2019/027992 WO2019204523A1 (en) | 2018-04-17 | 2019-04-17 | Bicyclic carboxamides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010879A true MX2020010879A (es) | 2020-11-09 |
Family
ID=66625250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010879A MX2020010879A (es) | 2018-04-17 | 2019-04-17 | Carboxamidas biciclicas y metodos de uso de las mismas. |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US10968201B2 (https=) |
| EP (1) | EP3781550B1 (https=) |
| JP (1) | JP7361713B2 (https=) |
| KR (1) | KR102815312B1 (https=) |
| CN (1) | CN112313208B (https=) |
| AU (2) | AU2019255717B2 (https=) |
| BR (1) | BR112020021042A2 (https=) |
| CA (1) | CA3096894A1 (https=) |
| DK (1) | DK3781550T3 (https=) |
| ES (1) | ES3010282T3 (https=) |
| IL (1) | IL277963B2 (https=) |
| MX (1) | MX2020010879A (https=) |
| SG (1) | SG11202010153WA (https=) |
| WO (1) | WO2019204523A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018255300B2 (en) * | 2017-04-18 | 2021-10-28 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| US11066405B2 (en) | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| IL277963B2 (en) | 2018-04-17 | 2024-09-01 | Tempest Therapeutics Inc | Bicyclic carboxamides and methods of use thereof |
| CN115448882A (zh) * | 2021-06-08 | 2022-12-09 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物 |
| CN115448913A (zh) * | 2021-06-08 | 2022-12-09 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的双环化合物 |
| CN114085167A (zh) * | 2021-12-13 | 2022-02-25 | 华中药业股份有限公司 | 一种杂质ts-3a的制备方法 |
| WO2024102968A1 (en) * | 2022-11-10 | 2024-05-16 | Tempest Therapeutics, Inc. | Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap) |
| CN118164967A (zh) * | 2022-12-08 | 2024-06-11 | 武汉人福创新药物研发中心有限公司 | 一种ep2、ep4受体拮抗剂 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| JP2007023028A (ja) * | 2005-06-16 | 2007-02-01 | Ono Pharmaceut Co Ltd | 内耳疾患治療剤 |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP2035376B1 (en) * | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| JP5301469B2 (ja) | 2007-02-26 | 2013-09-25 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| JP5408434B2 (ja) * | 2007-07-03 | 2014-02-05 | アステラス製薬株式会社 | アミド化合物 |
| EP2565191B1 (en) * | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010121382A1 (en) * | 2009-04-21 | 2010-10-28 | Merck Frosst Canada Ltd. | Process for making indole cyclopropyl amide derivatives |
| RU2560818C2 (ru) | 2009-04-21 | 2015-08-20 | Эппл Инк | Способ и устройство для определения индикатора качества канала в сетях связи, работающих в режиме mu-mimo |
| EP3375791A1 (en) | 2009-09-30 | 2018-09-19 | Memorial Sloan Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| CN103167875A (zh) * | 2010-08-17 | 2013-06-19 | 阿勒根公司 | 用于治疗角膜浑浊的ep2或ep4激动剂 |
| EP2760862B1 (en) * | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9655887B2 (en) | 2013-05-23 | 2017-05-23 | Bayer Pharma Aktiengesellschaft | Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception |
| TWI695831B (zh) * | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
| CN108430992A (zh) * | 2015-12-17 | 2018-08-21 | 阿斯特克斯医疗公司 | 作为h-pgds抑制剂的喹啉-3-甲酰胺 |
| TWI730032B (zh) * | 2016-01-13 | 2021-06-11 | 美商必治妥美雅史谷比公司 | 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物 |
| HUE057799T2 (hu) | 2016-07-07 | 2022-06-28 | Ono Pharmaceutical Co | EP4 antagonistát és immunellenõrzõpont gátlót tartalmazó kombináció |
| AU2018255300B2 (en) * | 2017-04-18 | 2021-10-28 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| US11066405B2 (en) | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| IL277963B2 (en) | 2018-04-17 | 2024-09-01 | Tempest Therapeutics Inc | Bicyclic carboxamides and methods of use thereof |
| CN115448882A (zh) | 2021-06-08 | 2022-12-09 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物 |
| CN119487006A (zh) | 2022-02-24 | 2025-02-18 | 广东新契生物医药科技有限公司 | 作为pge2受体拮抗剂的酰胺化合物 |
-
2019
- 2019-04-17 IL IL277963A patent/IL277963B2/en unknown
- 2019-04-17 WO PCT/US2019/027992 patent/WO2019204523A1/en not_active Ceased
- 2019-04-17 MX MX2020010879A patent/MX2020010879A/es unknown
- 2019-04-17 DK DK19725441.0T patent/DK3781550T3/da active
- 2019-04-17 CA CA3096894A patent/CA3096894A1/en active Pending
- 2019-04-17 KR KR1020207032916A patent/KR102815312B1/ko active Active
- 2019-04-17 SG SG11202010153WA patent/SG11202010153WA/en unknown
- 2019-04-17 CN CN201980040841.6A patent/CN112313208B/zh active Active
- 2019-04-17 JP JP2020555164A patent/JP7361713B2/ja active Active
- 2019-04-17 US US16/387,294 patent/US10968201B2/en active Active
- 2019-04-17 BR BR112020021042-0A patent/BR112020021042A2/pt active IP Right Grant
- 2019-04-17 EP EP19725441.0A patent/EP3781550B1/en active Active
- 2019-04-17 ES ES19725441T patent/ES3010282T3/es active Active
- 2019-04-17 AU AU2019255717A patent/AU2019255717B2/en active Active
-
2020
- 2020-10-14 US US17/070,554 patent/US11472789B2/en active Active
-
2022
- 2022-06-23 US US17/847,811 patent/US11795156B2/en active Active
-
2023
- 2023-02-28 AU AU2023201228A patent/AU2023201228A1/en not_active Abandoned
- 2023-09-14 US US18/467,022 patent/US12215093B2/en active Active
-
2024
- 2024-12-19 US US18/988,376 patent/US20250353829A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL277963B2 (en) | 2024-09-01 |
| BR112020021042A2 (pt) | 2021-01-19 |
| AU2023201228A1 (en) | 2023-04-06 |
| US11472789B2 (en) | 2022-10-18 |
| US10968201B2 (en) | 2021-04-06 |
| AU2019255717B2 (en) | 2022-12-08 |
| AU2019255717A1 (en) | 2020-11-26 |
| JP2021521128A (ja) | 2021-08-26 |
| SG11202010153WA (en) | 2020-11-27 |
| CN112313208B (zh) | 2024-04-19 |
| US20190315712A1 (en) | 2019-10-17 |
| WO2019204523A1 (en) | 2019-10-24 |
| US20250353829A1 (en) | 2025-11-20 |
| EP3781550B1 (en) | 2024-10-30 |
| ES3010282T3 (en) | 2025-04-02 |
| US20230045612A1 (en) | 2023-02-09 |
| JP7361713B2 (ja) | 2023-10-16 |
| US12215093B2 (en) | 2025-02-04 |
| CA3096894A1 (en) | 2019-10-24 |
| US20210024491A1 (en) | 2021-01-28 |
| US11795156B2 (en) | 2023-10-24 |
| IL277963B1 (en) | 2024-05-01 |
| DK3781550T3 (da) | 2025-01-27 |
| EP3781550A1 (en) | 2021-02-24 |
| KR20210003166A (ko) | 2021-01-11 |
| CN112313208A (zh) | 2021-02-02 |
| US20240150316A1 (en) | 2024-05-09 |
| KR102815312B1 (ko) | 2025-05-30 |
| IL277963A (en) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010879A (es) | Carboxamidas biciclicas y metodos de uso de las mismas. | |
| ZA201903091B (en) | Methods of treating inflammatory conditions | |
| MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
| TW200612926A (en) | Compounds and compositions as ppar modulators | |
| MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
| UA122868C2 (uk) | Тетрагідропіридо[3,4-в]індолові модулятори естрогенових рецепторів та їх застосування | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| EP2576549A4 (en) | Bicyclic Heteroarylkinase Inhibitors and Methods of Use | |
| MX379811B (es) | Citocinas quimiotácticas como moduladores de los receptores ccr2 y el uso de las mismas en el tratamiento de enfermedades | |
| TN2011000171A1 (en) | Isonicotinamide orexin receptor antagonists | |
| MX2007009356A (es) | Compuestos y composiciones como moduladores de ppar. | |
| CR20210580A (es) | Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b | |
| CR20210615A (es) | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b | |
| MX2021015510A (es) | Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b. | |
| MX2021015508A (es) | Carbamatos de piridina y su uso como moduladores del receptor glun2b. | |
| TW200505904A (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
| TW200602330A (en) | Compounds and compositions as PPAR modulators | |
| MX2011010782A (es) | Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. | |
| WO2015100092A3 (en) | 7-beta analogs of orvinols | |
| PH12012502070A1 (en) | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| MX2023005408A (es) | Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. | |
| MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| MX381768B (es) | Combinación de antagonistas puros del receptor 5-ht6 con inhibidores de la acetilcolinesterasa. |